<unk> , sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.<unk>  was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that<unk>  effectively reversed anticoagulation caused by dabigatran within minutes. It was approved for medical use in the United States and in the European Union in 2015.
Idarucizumab
Brolucizumab
Etaracizumab
Risankizumab
Mogamulizumab
Caplacizumab
Tildrakizumab
Ixekizumab